Communiqués Stoke Therapeutics, Inc.

Actions

STOK

US86150R1077

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
28,43 ^USD	-1,73%		-2,07%	-10,43%

04/09	Stoke Therapeutics et Biogen présentent des données cliniques à long terme confirmant le potentiel de modification de la maladie du zorevunersen dans le syndrome de Dravet	CI
04/08	Stoke Therapeutics, Inc. : Opinion positive de Wedbush	ZM

Communiqués

16/09	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU
04/09	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	AQ
04/09	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)	BU
02/09	Stoke Therapeutics to Present at the Cantor Global Healthcare Conference	BU
01/09	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)	BU
01/09	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)	AQ
18/08	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU
05/08	Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference	BU
03/08	Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates	BU
27/07	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates	BU
16/07	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU
13/07	Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer	BU
30/06	Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	BU
16/06	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU
28/05	Stoke Therapeutics to Present at Upcoming Investor Conferences in June	BU
18/05	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU
08/05	Stoke Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
08/05	Stoke Therapeutics : STOK Q1 2026 Webcast Slides FINAL	PU
07/05	Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates	BU
30/04	Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates	BU
16/04	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU
08/04	Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference	BU
08/04	Stoke Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
07/04	Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors	BU
17/03	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU